Study identifier:D5890L00032
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, double blind, placebo controlled, parallel-group study with use of budesonide/formoterol "as-needed", or terbutaline "as-needed" or regular use of budesonide + terbutaline "as-needed", in patients with mild intermittent asthma
Exercise induced asthma
Phase 2
No
budesonide, terbutaline, budesonide/formoterol
All
66
Interventional
12 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: A budesonide 400yg + terbutaline 0.4 mg as-needed | Drug: budesonide 400 yg x 1 Other Name: Pulmicort Turbuhaler Drug: terbutaline 0.4 mg as-needed Other Name: Bricanyl Turbuhaler |
Active Comparator: B placebo + terbutaline 0.4 mg as-needed | Drug: terbutaline 0.4 mg as-needed Other Name: Bricanyl Turbuhaler |
Active Comparator: C placebo + budesonide/formoterol 160/4.5 yg as-needed | Drug: budesonide/formoterol 160/4.5 yg as-needed Other Name: Symbicort Turbuhaler |